Skip to main content

Table 3 Events (cardiac death or heart transplantation) according to baseline characteristics (A) and blood pressure profile (B)

From: Prognostic value of systolic short-term blood pressure variability in systolic heart failure

A.
Baseline characteristics Event (n = 70) No event (n = 218) p
Age, years 62 ± 12 59 ± 12 0.1
Male, n (%) 60 (86) 167 (77) 0.1
BMI 25.2 ± 3.6 26.2 ± 5.8 0.03
NYHA I &II, n (%) 18 (26) 135 (62) <0.001
NYHA III&IV, n (%) 52 (74) 83 (38)
LVEF, % 27 ± 10 29 ± 9 0.2
Congestive HF, n (%) 39 (55) 83 (38) <0.05
Diabetes, n (%) 19 (27) 42 (19) 0.16
Hypertension, n (%) 22 (31) 103 (47) 0.02
Ischemic, n (%) 34 (49) 97 (44) 0.5
Cockcroft, ml/min 64 ± 24 72 ± 28 <0.05
Heart rate, bpm 79 ± 15 79 ± 18 0.8
ACE inhibitor, n (%) 54 (77) 187 (86) 0.09
ARA2, n (%) 7 (10) 12 (6) 0.19
Spironolactone, n (%) 34 (49) 106 (49) 0.99
B-blockers, n (%) 38 (54) 141 (65) 0.12
Ca-channel blockers, n (%) 1 (1) 12 (6) 0.15
Nitride, n (%) 12 (17) 43 (20) 0.6
Diuretics, n (%) 66 (94) 182 (83) 0.02
B.
Blood pressure profile Event (n = 70) No event (n = 218) p
SBP 24-h, mmHg 107 ± 15 111 ± 15 0.05
SBP daytime, mmHg 108 ± 16 113 ± 15 0.03
SBP nighttime, mmHg 104 ± 15 108 ± 17 0.13
DBP 24-h, mmHg 66 ± 9 69 ± 9 0.06
DBP daytime, mmHg 68 ± 9 71 ± 10 <0.05
DBP nighttime, mmHg 64 ± 10 66 ± 11 0.24
DIP, mmHg 3.4 ± 5 4.5 ± 7 0.23
PP daytime, mmHg 40 ± 11 42 ± 10 0.13
PP nighttime, mmHg 40 ± 11 42 ± 11 0.22
BPV daytime, mmHg 22 ± 6 24 ± 9 <0.05
BPV nighttime, mmHg 17 ± 6 18 ± 8 0.4
  1. ACE angiotensin converting enzyme, ARA2 angiotensin 2 receptor antagonist, BMI body mass index, LVEF left ventricular ejection fraction, NYHA New York Heart Association, BPV blood pressure variability, DBP diastolic blood pressure, PP pulse pressure